Bromhexine, another potent TMPRSS2-specific protease inhibitor, was identified through large-scale chemical library screening and was demonstrated to lower the risk of metastasis in prostate cancer with no systemic toxicity shown [122]. Here, TMPRSS2 is linked to prostate cancer.